BIIB
Biogen Inc. NASDAQ$187.06
After hrs
$187.21
+0.00%
Mkt Cap $27.4B
52w Low $115.25
82.4% of range
52w High $202.41
50d MA $184.91
200d MA $163.84
P/E (TTM)
21.1x
EV/EBITDA
9.6x
P/B
1.5x
Debt/Equity
0.4x
ROE
9.3%
P/FCF
12.6x
RSI (14)
—
ATR (14)
—
Beta
0.16
50d MA
$184.91
200d MA
$163.84
Avg Volume
1.3M
About
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for th…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | TNS | 3.05 | 3.57 | +17.0% | 194.38 | -0.2% | -2.6% | -3.8% | — | — | — | — | — |
| Feb 6, 2026 | TNS | 1.63 | 1.99 | +22.1% | 201.18 | -0.7% | -3.7% | -6.1% | -5.0% | -2.8% | -2.3% | -6.4% | — |
| Oct 30, 2025 | TNS | 3.88 | 4.81 | +24.0% | 149.61 | -1.1% | +3.1% | +1.2% | -0.2% | +2.6% | +4.8% | +18.8% | — |
| Jul 31, 2025 | TNS | 3.90 | 5.47 | +40.3% | 128.00 | +0.8% | +3.1% | +3.3% | +3.8% | +1.0% | -0.2% | +9.1% | — |
| May 1, 2025 | TNS | 2.90 | 3.02 | +4.1% | 120.93 | +1.2% | +2.1% | +0.7% | -3.4% | -3.1% | -2.1% | +8.4% | — |
| Feb 12, 2025 | TNS | 3.43 | 3.44 | +0.3% | 133.43 | -1.0% | +3.8% | +2.9% | +2.4% | +2.4% | +2.7% | +4.5% | — |
| Oct 30, 2024 | TNS | 3.77 | 4.08 | +8.2% | 181.18 | -1.7% | -4.0% | -4.1% | -4.2% | -2.3% | -3.7% | -11.3% | — |
| Aug 1, 2024 | TNS | 4.07 | 5.28 | +29.7% | 210.70 | +0.8% | -2.4% | -5.8% | -5.0% | -5.2% | -3.1% | -2.8% | — |
| Apr 24, 2024 | TNS | 3.47 | 3.67 | +5.8% | 201.99 | -0.4% | +0.2% | +3.4% | +6.7% | +6.4% | +7.0% | +7.8% | — |
| Feb 13, 2024 | TNS | 3.16 | 2.95 | -6.6% | 226.65 | +0.2% | -2.6% | -1.5% | -3.3% | -3.3% | -2.4% | -3.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Citigroup | Maintains | Neutral → Neutral | — | $189.28 | $189.28 | +0.0% | -1.2% | — | — | — | — |
| Apr 30 | RBC Capital | Maintains | Outperform → Outperform | — | $194.38 | $194.02 | -0.2% | -2.6% | -3.8% | — | — | — |
| Apr 30 | Guggenheim | Maintains | Buy → Buy | — | $194.38 | $194.02 | -0.2% | -2.6% | -3.8% | — | — | — |
| Apr 30 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $194.38 | $194.02 | -0.2% | -2.6% | -3.8% | — | — | — |
| Apr 30 | Wedbush | Maintains | Neutral → Neutral | — | $194.38 | $194.02 | -0.2% | -2.6% | -3.8% | — | — | — |
| Apr 22 | UBS | Upgrade | Neutral → Buy | $225 | $185.95 | $189.31 | +1.8% | +2.2% | +1.0% | -0.8% | -2.8% | -1.4% |
| Apr 20 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $177.35 | $179.54 | +1.2% | +3.4% | +4.8% | +7.2% | +5.9% | +4.0% |
| Apr 14 | Piper Sandler | Upgrade | Neutral → Overweight | — | $176.37 | $177.71 | +0.8% | +1.5% | +2.4% | -0.2% | +0.6% | +4.0% |
| Apr 13 | Citigroup | Maintains | Neutral → Neutral | — | $172.97 | $172.62 | -0.2% | +2.0% | +3.5% | +4.4% | +1.8% | +2.5% |
| Apr 13 | Truist | Maintains | Hold → Hold | — | $172.97 | $172.62 | -0.2% | +2.0% | +3.5% | +4.4% | +1.8% | +2.5% |
Recent Filings
8-K
Biogen Inc. -- 8-K Filing
Biogen demonstrated strong financial momentum with Non-GAAP EPS growing 31% year-over-year and LEQEMBI sales surging 74%, signaling successful commercial execution across its neurology portfolio.
Apr 29
8-K
Unknown — 8-K Filing
This standard safe harbor language indicates Biogen is protecting itself from litigation over forward-looking statements, suggesting management made optimistic projections investors should scrutinize carefully for accuracy.
Apr 6
8-K
Unknown — 8-K Filing
Biogen is acquiring Apellis for an upfront payment plus contingent value rights, signaling aggressive expansion into complement-driven therapies and providing Apellis shareholders a defined exit with potential earn-out upside.
Mar 31
8-K
Unknown — 8-K Filing
I need more substantive information from the 8-K filing to provide meaningful analysis. The summary provided only contains technical metadata about the document format rather than actual business content or events that would impact BIIB's stock.
Could you provide the actual filing details, such as material events, executive changes, financial updates, or strategic announcements?
Mar 11
8-K
Biogen Inc. -- 8-K Filing
I cannot provide a meaningful analysis of this filing as the summary contains only technical XBRL metadata and schema references without substantive business information about Biogen's actions or events.
Feb 11
8-K
Biogen Inc. -- 8-K Filing
Biogen's SKYCLARYS generated $78 million in global sales with 30% patient growth in Q4 2025, signaling strong commercial traction for this rare disease treatment.
Feb 6
Data updated apr 24, 2026 9:37pm
· Source: massive.com